New drugs for rheumatoid arthritis [4]

New England Journal of Medicine

Volumn 351, Issue 9, 2004, Pages 937-938

  Messori, Andrea ^a   Santarlasci, Benedetta ^a   Vaiani, Monica ^a  

^a Laboratorio SIFO di Farmacoeconomia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NEW DRUG; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; META ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; META-ANALYSIS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4143150526     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200408263510922     Document Type: Letter

References (4)

1. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
2. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
3. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
4. Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ 2000;32:1103-6.